Posts

Disclaimer: The captions in this video are auto-generated and may contain inaccuracies.

Professor Angus Dalgleish

Professor Angus Dalgleish, M.D., F.R.C.P., F.R.A.C.P., F.R.C.Path, F.Med.Sci is a renowned oncologist practicing in the United Kingdom, who splits his time between clinical patient care and research. Prof. Dalgleish serves as an advisor to a number of biopharmaceutical companies and is a principal investigator in several clinical trials. Prof. Dalgleish has been a Professor of Medical Oncology at St George’s University of London and Consultant Physician at St George’s Hospital since 1991. He has served as the President of the Clinical Immunology and Allergy Section of the Royal Society of Medicine. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists.

Prof. Dalgleish studied Medicine at University College London, where he obtained an MBBS and a BSc in Anatomy. Among his main interests are: immunology and melanoma, use of anti-angiogenic agents & low dose chemotherapy in resistant solid tumor disease of the prostate, colon & breast. A clinical researcher of international repute, he has made significant contributions to the study of the immunological basis of AIDS and to the field of cancer vaccines. He is the current Principal of the Cancer Vaccine Institute.

To view his bio, click on Prof. Angus Dalgleish’s profile

To view his published articles, click on Prof. Angus Dalgleish’s Work

Copied from: https://www.ldnscience.org/ldn/ldn-researchers/angus-dalgleish

Doctor Paul Marik

Prior to co-founding the FLCCC, Dr. Marik was best known for his revolutionary work in developing a lifesaving protocol for sepsis, a condition that causes more than 250,000 deaths yearly in the U.S. alone.

Dr. Marik is an accomplished physician with special knowledge in a diverse set of medical fields, with specific training in Internal Medicine, Critical Care, Neurocritical Care, Pharmacology, Anesthesia, Nutrition, and Tropical Medicine and Hygiene. He is a former tenured Professor of Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School (EVMS) in Norfolk, Virginia. As part of his commitment to research and education, Dr. Marik has written over 500 peer-reviewed journal articles, 80 book chapters and authored four critical care books and the Cancer Care Monograph. His efforts have provided him with the distinction of the second most published critical care physician in the world. He has been cited over 54,500 times in peer-reviewed publications and has an H-index of 111. He has delivered over 350 lectures at international conferences and visiting professorships. As a result of his contributions, he has been the recipient of numerous teaching awards, including the National Teacher of the Year award by the American College of Physicians in 2017.

In January 2022 Dr. Marik retired from EVMS to focus on continuing his leadership of the FLCCC and has already co-authored over 10 papers on therapeutic aspects of treating COVID-19. In March 2022 Dr. Marik received a commendation by unanimous vote by the Virginia House of Delegates for “his courageous treatment of critically ill COVID-19 patients and his philanthropic efforts to share his effective treatment protocols with physicians around the world.”

Copied from: https://covid19criticalcare.com/experts/paul-e-marik/

Dr Jeyanthi Kunadhasan

Is an anesthetist and perioperative physician from Victoria, Australia.

She has been in medical leadership at her previous hospital as well as statewide; as chair of the Medical Senior Group representing consultant doctors,
as well as a previous chair of the Advisory Committee of Blood Matters Victoria.

Her clinical interest is Patient Blood Management, where she spearheaded many initiatives that sustainably brought down the unnecessary transfusion rates in major surgeries, leading to improved patient outcomes and lower costs to the health system.

In December 2021, when vaccine mandates were rolled out, Dr. Kunadhasan requested a risk assessment. Her goal in doing so was to warn her employer at the time about the risks of the shots, while at the same time trying to keep her job and avoid taking the injection herself. Unfortunately, instead of taking a pause and considering Dr. Kunadhasan’s request, in December 2021, Dr. Kunadhasan was fired by her employer.

She is currently the treasurer of the Australian Medical Professionals Society (AMPS).

Dr. Kunadhasan is also the lead author on “Report 42, Pfizer’s EUA Granted Based on Fewer Than 0.4% of Clinical Trial Participants. FDA Ignored Disqualifying Protocol Deviations to Grant EUA” and subsequently wrote two articles in Spectator Australia, explaining her findings in the Pfizer documents.

Copied from: https://wowintl.org/jeyanthi-kunadhasan

Three years ago, I promised to hound down those who perpetrated the greatest crime in Australian history — COVID — and I will continue to do so.

I have addressed the Senate five times now to explain the latest data that shows the harm being caused to everyday Australians from our COVID response, including the mRNA injections.

This is my sixth update on COVID science, using new, peer-reviewed published papers, referenced by the lead author. (References detailed on my website).

The shocking data shows that COVID mRNA injections have negative efficacy and harms more people than they protect. Even more concerning, the latest report shows that children who were injected with mRNA “vaccines” not only all contracted COVID but are now more likely to develop cancer over their lifetimes.

It’s time to call for a Royal Commission!

I will return to this crime of the century in December during my third COVID inquiry, titled “COVID on Trial”, featuring leading Australian and international doctors and lawyers, and presented before cross-party Members of Parliament.

Transcript

Three years ago I promised to hound those who perpetrated the greatest crime in Australian history, and I will continue to do so. Here’s the latest evidence of COVID-19 being the crime of the century, taken from new, peer-reviewed, published papers referenced to the lead author. In the Polish Annals of Medicine publication, FIRN conducts a limited literature review of the progression and reporting of COVID-19 vaccine severe adverse events, or SAE, in scientific journals, finding: ‘The literature has gone from claiming there are absolutely no SAEs from mRNA based vaccines in 2021 to an acknowledgement of a significant number of various SAEs by 2024. These adverse events include neurological complications, myocarditis, pericarditis and thrombosis.’ FIRN said, ‘This warns that science should be completely objective when evaluating health risk, because social and economic considerations often influence.’ 

Why has it taken three years for the medical community to find its voice? Firstly, it takes time to do the work to produce a peer-reviewed study, especially one critical of its pharmaceutical industry masters. Secondly, money talks. All the big pharma research money, grants, fake conferences and lavish destinations are a hard influence to overcome. Big pharma money is now going in so many different directions. Like the proverbial boy with his finger in the dyke, cracks are finally appearing. That’s why the misinformation and disinformation bill has been advanced: to get rid of these embarrassing truths in time for the next pharmaceutical industry fundraiser. 

Only in the last year have scientists been able to publish articles that acknowledge a high number of serious adverse events, or SAEs, linked to the mRNA based vaccines. There’s so much in recent published science that most people are unaware of because of pharmaceutical industry control. Here are the recent top 10 reasons to lock the bastards up. There is the Thacker study. Speed may have come at the cost of data integrity and patient safety, finding FISA falsified and misrepresented data. There is the Facsova study. A study of 99 million doses found clear proof of myocarditis, pericarditis and cerebral thrombosis, and the study extend only for 42 days after each dose, yet we know people are dropping dead suddenly years after they took one in the arm for big pharma. The Fraiman study found the excess risk of serious adverse events of special interest was higher than the risk reduction for COVID-19 hospitalisation relative to the placebo group in both Pfizer and Moderna trials, yet they never said more people would get seriously ill from the injections. The Benn study found no statistically significant decrease in COVID-19 deaths in the mRNA vaccine trials, while there was actually a small increase in total deaths. Doshi and Lataster’s study highlighted counting window failures—that is, how long after injection before an adverse event was counted. Pfizer and their cronies did not count adverse events in the first week after injection, which is when many occurred, and stopped counting after six weeks. This likely led to exaggerated effectiveness and misleading safety pronouncements, including serious adverse events being apportioned to unvaccinated people. The Raethke study noted a rate of serious adverse vaccine reactions of approximately one per 400 people—astonishing! 

Mostert’s study drew attention to the baffling problem of people dying suddenly years after injection, suggesting it may be the thing they were injected with that caused it. Lataster’s study from the University of Sydney, who provided input to this speech, demonstrated there are correlations between COVID-19 vaccination and European excess deaths and found that COVID injections increased the chance of COVID-19 infection and even the chance of COVID-19 death. The Furst study provided evidence that a healthy vaccine participant bias is at play. They only studied healthy people. That further implies that the effectiveness of the COVID-19 vaccines is being exaggerated, beyond the effects of counting window issues and other data manipulations. 

This brings us to the latest peer reviewed and published paper from Robin Kobbe and others. It studied children five to 11 years old one year after they had taken Pfizer mRNA vaccines, showing an elevated risk of developing cancer during their entire lives. Published on 30 July 2024 in the Pediatric Infectious Disease Journal, this report studied German children who had two Pfizer injections. This was a longitudinal study following healthy kids through two doses of vaccinations, with the resulting damage clearly attributed to the mRNA injections. 

I’ll return to this crime of the century in December when I conduct by third COVID inquiry called ‘COVID under trial’ with leading Australian and international doctors, lawyers and politicians, which will be held before cross-party members of parliament. I promise to hound down this crime’s perpetrators, and I will do exactly that. 

References

https://okaythennews.substack.com/p/covid-vaccine-science-catching-up

https://doi.org/10.29089/paom/193801

Labor is still running a COVID cover-up. Australians deserve a Royal Commission and true accountability for the wrongs committed over COVID, not this delayed whitewash review.

Transcript

Chris Smith:  Labor has delayed the public release of its Covid 19 review. What is the government afraid of to show, do you think? 

Senator ROBERTS: Review? You’d hardly call it a review, Chris. I think you’re being very, very kind. Look, the panelists were biased – they were lock-down supporters. They’re not allowed to look at the state responses. They’ve got no investigating powers – investigative powers. They’ve got no power to compel evidence, compel documents, compel witnesses. This is just a sham. It is to get at Morrison and Morrison should be got at. He deserves to be really hammered on this, but he’s no more guilty than, well he’s just as guilty rather as the state premiers who were mostly Labor. This is a protection racket for the Labor premiers and the Labor bureaucrats. We need a royal commission now! 

Chris Smith: You see, I would have thought the Royal Commission needs to look at two things that that so-called review is not even touching. The states, as you mentioned and their role when it came to lock-downs and all kinds of freebies that were handed out to the public. But also on top of that, the deals that were done with big Pharma over those damn vaccines that have proved to be a con themselves. 

Senator ROBERTS: I agree with you entirely. There are, in fact, there are many, many areas that need to be looked at Chris. I moved a motion to get one of the committees, in the Senate, to investigate and developa draft terms of reference for a possible royal commission, and that was passed through the Senate, that the committee did it. And I want to commend former barrister Julian Gillespie. He pulled an enormous team together and developed a phenomenal submission, 180 pages I think it was, 46,000 signatures. It was the people’s submission. And it covered – it turned it into a de facto inquiry into Covid and it covers everything. And the royal, the chair – Paul Scarr, I must say and the committee did a phenomenal job, along with the Secretariat, of pulling that into something that’s very, very workable. There is a draft terms of reference ready to go. And they’re completely comprehensive, cover every topic imaginable.  

In a recent senate estimate session, I highlighted the alarming ethnic disparities in COVID-19 mortality rates. Australians from the Middle East died at three times the average death rate, those from Southern Europe twice as high, while sub-Saharan Africans had lower mortality rates. 

What’s driving these disparities? The health experts suggest that low vaccine coverage and socioeconomic factors played roles in these differences. As vaccination efforts improved, mortality rates began to align more closely with the general population. 

These are just theories, not explanations, and it comes across as a lazy response. There’s no justification for not making an effort to understand the reasons behind such a serious medical issue.

Transcript

Senator ROBERTS: Professor Kelly, you previously brought someone forward to talk about the differences in incidence and severity with a low-socioeconomic profile.  

Prof. Kelly: Mr Gould, yes.  

Senator ROBERTS: Australian residents from the Middle East died at three times the population mean, those from Southern Europe were twice as likely to die and those from North Africa were almost three times as likely to die; however, sub-Saharan Africans were less likely to die. Why are we seeing ethnic differences in COVID mortality in Australia? I understand that ‘ethnic’ is to do with culture.  

Dr Gould: Yes. Just talking around the numbers involved, as you say, the ABS has reported, during various stages of the pandemic, mortality rates for people born in different countries and, as you’ve said, there are higher mortality rates for people born in places such as the Middle East. There are a number of potential reasons for that. One of the areas that I discussed in my previous answer, which I think is relevant, is that, for a lot of those communities, initially, vaccine coverage rates were low. So significant work was done during the course of the pandemic to work with those communities to increase the coverage rate, and we really saw quite a dramatic shift during the course of the pandemic in the variation in mortality rates between these communities in the general Australian population; to a large degree, they came into line with the general population experience, so that was a positive outcome. Certainly, there’s an indication that the vaccine rates would have had a role to play. We did talk as well about socioeconomic status. We do know that, for some language groups or groups born in different countries, those rates may correlate with different socioeconomic status as well, so there may be some relationships there.  

Senator ROBERTS: So there’s an overlap, potentially, in some areas? 

Dr Gould: Potentially, yes. It’s not broadly always the case. We find that a lot of recent, skilled migrants live in high socioeconomic areas, so it’s difficult to make a broad generalisation there. 

As a Scientist and former vet school Dean, Professor Rose became concerned that critical information about SARs-CoV2 virus and COVID-19 vaccines was not being reported by mainstream media.

We discussed how the world and particularly Australia changed with the arrival of COVID and how the population seems to have forgotten the drastic restrictions that were put on our freedoms. We also discussed what, if any, lessons were learned.

Reuben received a notice from YouTube that he had “breached community guidelines” and the link to his channel can no longer be accessed.

You can search for more of Reuben’s work here: https://reubenrose.substack.com/ | Sons of Issachar Newsletter | www.inancientpaths.com

I called on the Senate to support the inquiry into the federal COVID-19 Vaccine Injury Claims Scheme and restated my demand for the people of Australia to have their Royal Commission in COVID.

Australians are dying at a far higher rate than normal. Surely even the pharma industry lobby in the Senate can see that there’s a high probability that the cause, the one thing that has changed in the last 4 years coinciding with the increased mortality, is the jabs that everyday Australians were coerced and bullied into taking.

Why is the Labor Government so afraid of uncovering the truth? If they’re confident it’s not the cause, then shouldn’t they be prepared to have an inquiry into it?

This is an issue of life or death for the Australian people and it needs to be above suspicion. We need honest debate and proper scrutiny to understand why over 30,000 people more than normal have died so far.

In this speech, I go further into messenger RNA “vaccines”, the technology used to protect them and the actual mechanism by which these jabs could be causing the harm we are seeing.

I also talk about the “bait and switch” that was used during clinical trials, which saw trials conducted using the long-established method of using albumin to grow the vaccine. After testing, this was switched out for a new and untested method using a derivative of E. coli bacteria, which multiples much faster but contaminates the vaccine in the process.

During an interview on the ABC, Greg Hunt, the Health Minister at the time, admitted that “The world is engaged in the largest clinical trial, the largest global vaccination trial ever, and we will have enormous amounts of data”.

Where is that data now and what does it really say about our COVID response? The answer will only come from an inquiry. Clearly the Albanese Government and the Opposition do not want you to know.

Transcript

There have been more than 25,000 deaths. That’s more than 25,000 homicides. At Senate estimates hearings last November I produced an independent analysis of Australian Bureau of Statistics data. It showed the unexplained increase in deaths for the period 2022-23—population adjusted, excluding COVID and respiratory deaths—was 13 per cent. The Australian Bureau of Statistics provided data using a different methodology, which agreed closely with my figure. An increase of 13 per cent above baseline on 195,000 deaths in 2022-23 means 25,000 more Australians died than expected. 

Did the novel COVID injections cause all of these deaths? While highly likely, it’s possible they did not. Were enough of these deaths caused by the injections to be of serious concern and to support an inquiry? Definitely yes. A common argument against having an inquiry is the issue that increases in mortality are due to many different causes—cancer, dementia, cardiac conditions and diabetes—so there can’t possibly be a single cause. An inquiry would need to explain this. In the absence of an inquiry, I’ll advance a theory from many credible medical authorities. I’ll do that in a minute. 

The COVID products are not vaccines because they don’t stop people getting COVID. They don’t stop people passing it on to someone else. I call them injections or jabs. The jabs include a segment of messenger RNA, which has the purpose of splicing a new segment into our DNA, which produces a protein to create an antibody to COVID-19. This raises the possibility that disease can be prevented, using mRNA techniques to get our bodies producing antibodies to stop cancer and disease in their tracks. This opportunity to play God has proven so intoxicating that many in our health industry have fallen for it; mRNA jabs are being defended with religious fervour. As with any religious zealotry, those who ask difficult questions like, ‘Why are so many people suddenly dying?’ are being treated in a way that is an afront to parliamentary process and civil government. This issue is life or death. It needs to be above honest debate and scrutiny. 

One potential explanation for increased mortality rates across a wide range of conditions is a scandal known as ‘plasmidgate’. This is technical, so I’ll use plain language and apologise to any specialist vaccinologists listening. Messenger RNA is too fragile to use in a vaccine. To protect the RNA sequence from damage, these COVID jabs use a new technique, wrapping each one in a protective coating called a lipid nanoparticle. This keeps the RNA intact on its journey from your arm to the nucleus of every cell in your body, where the coating helps the RNA enter the cell and bind with your existing DNA. Remember, there are billions of mRNA particles in every jab. 

The manufacturing process is not clean. Fragments of DNA are being picked up in the manufacturing process and getting coated in that protective layer as well, a coating that stops your body expelling the fragment. These fragments are coming from the E. coli bacteria, a derivative being used to grow on the mRNA. Yes, they’re using modified E. coli bacteria as the growing medium for the mRNA in these jabs. 

The clinical trials for this product were conducted using the previous growing method, albumen from eggs. That’s the clinical trials. Yet that was far too slow for Pfizer, claiming the so-called speed of science. So, after the clinical trials were tested, with a conventionally propagated product, Pfizer switched it out for one grown using the much faster E. coli bacteria method. Has E. coli ever been used before as a medium to grow on a vaccine? No, it hasn’t. No, it has not. Was any safety testing done? Well, that would be every person that has had done the jab. That’s where the testing was done, if you’ve had the jab. Now people are dying, and the mRNA vaccine zealots are ignoring the outcome. The crime of the century is that the Australian public have been injected with DNA from E. coli bacteria that was wrapped up in a protective coating and delivered into the nucleus of every cell in your body. 

It gets worse. The latest peer reviewed published data on this shows that, in a third of cases, the cell will not produce the antibody intended against COVID and instead will produce some other antibody—in a third of cases. It’s a process called frame shifting, which means the mRNA does not present itself to your DNA strand correctly and accordingly combines with your DNA in an unintended way before producing an unintended protein antibody. This is going on in people’s bodies right now. What does that mutant protein do to your system? Nobody knows. Here’s the final crime. These mutant proteins are not created in one-third of people; they’re created in one-third of cells, meaning that everyone who was injected with a COVID product has a third of their cells now producing mutant proteins. We don’t know what harm that will cause. The harm varies from person to person. 

Are these proteins now resting in our brain? Are they? We know it can cross the blood-brain barrier into our brains. Are these proteins resting in our hearts, in our livers, in female ovaries, in male testes? Is it turning off our body’s natural cancer defence, resulting in turbo cancers? Highly likely. These are questions, not statements. When some of the most highly qualified medical professionals on this topic are asking questions, there is no excuse not to be investigating when those questions are being asked. It’s time to treat the zealots of the religion of mRNA as the maniacs they are. They played God and they harmed people. They killed tens of thousands of people. They committed homicide—homicidal maniacs. 

As a servant to the people of Queensland and Australia, I support this motion from Senator Rennick, which will find out how bad the damage is, and, once again, I call on the Senate to demand a royal commission into the crime of the century. 

The PRESIDENT: The question is that the motion moved by Senator Rennick be agreed to. 

The Senate divided. [12:18]  

(The President—Senator Lines)  

Until a few years ago, new vaccines and drugs were required to have local safety testing and went through a process that took years. This ensured a high degree of safety. During the COVID period, the Therapeutics Goods Administration (TGA) waved approvals through for new technologies (e.g. mRNA injections) and new drugs in a matter of months. Included in this new streamlined approval process were Molnupiravir and Remdesivir.

Remdesivir was refused approval for 20 years owing to serious side effects in trials, including death. Molnupiravir also has a long history of failure. There are multiple studies out recently that show it is simply not effective against COVID, and yet this is the #1 drug on the Pharmaceutical Benefits Scheme. Australia spends $650m a year on Molnupiravir.

I asked why we approved a drug with so much evidence showing negative efficacy and fatal outcomes, including cancer, to replace the Ivermectin + Zinc combo, which costs a fraction of the price and has been proven safe and effective across many years.

I also raised the question of who supervises the supervisor — the TGA. “Nobody” was the response. That answer highlighted the overly cosy relationship between the international pharmaceutical movement and Australian pharmaceutical companies. The TGA requires further inquiry.

A Royal Commission is the only institution in Australia with the powers of inquiry to understand how the TGA has gone from regulator to administrator, seemingly with none of the customary vigilance.

Transcript

Senator ROBERTS: My questions are to the TGA, and these questions go to the approval for molnupiravir. This is a drug developed in 2014 to treat encephalitis. It was then repurposed for influenza but was discontinued after concerns it was mutagenic. Merck then bought the company and used their influence with regulators—such as the TGA, apparently—to have the product approved as a treatment for COVID. This was on the back of a single trial where the preliminary results supported the application but the final results showed that, if anything, it had negative efficacy. Given the weight of evidence, in study after study, that molnupiravir has zero to negative efficacy, why is it still approved?

Prof. Lawler: While one of our medical officers, Dr Kaye Robertson, comes to the table to respond, I would just highlight a couple of things. I take the comment that you made that the drug company used its influence on the TGA. There is a process that we follow, obviously, in the evaluation of all medications. Sponsors bring them for evaluation of safety, quality and efficacy, and that’s the process that is undertaken, rather than one of influence. I think it’s important to note that. In terms of the question you raised around why the medication is still approved for the indication that it has, I’ll ask Dr Kaye Robertson to respond to that.

Dr Robertson: The TGA considered the evidence to support the approval of molnupiravir from the dossier that was submitted by the sponsor, in accordance with our standard processes, and drew the conclusion that, at the time, the benefits outweighed the risks. In terms of the specifics of any subsequent information that has been provided to the TGA, I am actually not in a position to comment with certainty. This is not the area I work in particularly, and I think we would be best advised, if the senator pleases, to take this question on notice and provide you with further detail.

Senator ROBERTS: I appreciate your giving that offer and I will accept your offer for the question to be answered on notice. It does surprise me that approval was given on a single trial where the preliminary results supported the application but the final results showed that, if anything, it had negative efficacy. The weight of evidence, in study after study, shows zero to negative efficacy, so I’m amazed that it’s still approved. The approval required Merck to continue to provide ongoing safety data and testing around mutagenicity and interaction with the mRNA vaccines. Have they done that, and does the data justify retaining approval?

Dr Robertson: I have before me the AusPAR that was published in relation to the studies that assessed the risk of mutagenicity. We can provide that to you in our response. I am reading from that, and it says: ‘Molnupiravir and NHC were mutagenic in the bacterial assay (with and without metabolic activation). Molnupiravir and NHC were not genotoxic in in vitro and in vivo micronuclei tests, and in vivo mutation assay at the cII locus (in Big Blue Transgenic F344 Rats). Equivocal results were obtained in an in vivo Pig-a mutagenicity assay … Carcinogenicity studies are not generally required for drugs for short term clinical use. However, the sponsor has initiated a short-term carcinogenicity in … mice.’ This was put to the clinicians on the ACM and other invited experts regarding this matter. It was considered at the time that, on balance, the drug remained to have a positive benefit-risk balance.

Prof. Lawler: I thank Dr Robertson for that response. I’d also just add, Senator, that, because you’re asking for some quite specific currency and comprehensiveness of ongoing postmarket reporting, we’ll take that on notice and bring that information back to you.

Senator ROBERTS: Thank you. In 2023 molnupiravir was top of the pops, Australia’s No. 1 drug, costing taxpayers $654 million last year, at $1,125 a prescription. Molnupiravir is 26 times more expensive than the out-of-patent ivermectin-plus-zinc combo, which is about $40 per prescription. And that’s what molnupiravir replaced—proven, safe and effective. Why are you spending $654 million—on something that is highly questionable as to its efficacy and its safety—when $25 million would have done?

Prof. Lawler: I can’t speak to the specifics of the amount spent on molnupiravir, but I can certainly indicate that the second amount that you said—I didn’t catch the amount—

Senator ROBERTS: The ivermectin-plus-zinc combo is $40 per prescription, and the total for the year would have been $25 million.

Prof. Lawler: I think that the comparison is flawed, in that there is no credible, supportable evidence that ivermectin and zinc is an effective treatment. So I’m not convinced that you are—

Senator ROBERTS: There is no credible evidence? There are 100 papers.

Prof. Lawler: I’m not convinced that the comparison is sound.

Senator ROBERTS: You based the decision on molnupiravir on one paper, and you’re ignoring 100 papers proving ivermectin’s success. Does anyone question the process—

CHAIR: Sorry, Senator Roberts; I’m going to give Professor Lawler an opportunity to respond to that.

Prof. Lawler: I didn’t hear a question.

Senator ROBERTS: The question is this: does anyone question the TGA’s processes—

Prof. Lawler: Yes.

Senator ROBERTS: for approving drugs? How often do you evaluate them?

Prof. Lawler: Drugs are—

Senator ROBERTS: Who audits them? Is there an independent auditor?

Prof. Lawler: I’m not sure which question you would like me to answer.

Senator ROBERTS: All of them.

CHAIR: Professor Lawler, are you clear on the question placed? There is a mixture of questions and assertions moving around here, so let’s just step back and, Senator Roberts, please place a question.

Senator ROBERTS: The question is: how often do you scrutinise your process, and is there an external auditor who does that who is qualified to do it and to assess the process?

Prof. Lawler: The processes that we follow are continually informed by our international collaboration and also by significant interaction with stakeholders, particularly the advisory committees that we have in respect of the assessments and evaluations that we undertake for products. We also undertake, obviously, the premarket review and evaluation of medicines and other therapeutic goods, and we undertake significant postmarket surveillance of the goods as well. We have outlined in significant detail on previous occasions the postmarket surveillance that we undertake. I might ask Mr Henderson to add to that.

Mr Henderson: Senator, I think you asked about the number of submissions or medicines that we evaluate. Just for context, at the moment there are about 150 applications that the TGA is evaluating for both new medicines and changes to indications to current medicines.

Senator ROBERTS: What is the point of telling me that?

Mr Henderson: Sorry; I thought you asked that as part of your question.

Senator ROBERTS: No, I didn’t ask for the number. Who are your stakeholders? Do they include the sponsors?

Prof. Lawler: As a contemporary regulator, we have a broad stable of stakeholders. They do include industry. As with any regulator, we work to refine our processes to balance the appropriate observance of safety, quality and efficacy with appropriate access and streamlining processes to bring products to market with a minimum of inappropriate regulatory burden. We undertake annual stakeholder engagement surveys to understand the views of the TGA, and the three key stakeholder groups that we survey on an annual basis are industry; health professionals—and obviously it’s important we work with health professionals for a number of ways, in that they both inform us and are informed by our decisions—and the community. It is notable that the responses we get reflect that the TGA, among all groups, comes across as a recognised, understood and valued regulator in the Australian healthcare system.

We have other stakeholders with whom we interact. We obviously interact very closely with the state health jurisdictions, and this is for a number of reasons. Our decisions on a number of elements, such as scheduling, for example, which we’ve already discussed today, have a significant impact on the state and territory poisons legislation and how they’re implemented for the delivery of medicines. We also interact quite closely with expertise across the regulatory sector. We have a number of advisory committees, the membership of which incorporates consumer views and expertise and also those from the academic and research sectors.

It’s also important to note that we obviously have close relationships with our international collaborative regulators. We are part of the International Coalition of Medicines Regulatory Authorities and the International Medical Device Regulators Forum, and we also work closely with individual regulators such as the MHRA and the UK, European Medicines Agency and the FDA.

CHAIR: Senator Roberts, I will shortly rotate the call to Senator Rennick and then can come back to you. Is this a sensible place to pause?

Senator ROBERTS: I’ll make it a short one, and then you’ll come back to me. Spike proteins can enter the body in two ways in the context of COVID: from the virus itself and from the vaccines. What work has the TGA done on the health outcomes of the long-term retention of spike proteins by the body after the mRNA vaccines that you recommended? It’s been four years now, so some good old-fashioned science by the TGA must be available. Is there any assessment?

Prof. Lawler: As has been indicated previously, as with all regulators around the world, we undertake a significant program of post-market surveillance and pharmacovigilance. This includes having a clear and well-communicated preference for adverse events post the vaccine to be reported. Those are reported and entered into our database of adverse event notifications, and, along with examination of that and also in collaboration with partner international regulators, we are very much aware and alive to emerging safety signals and act accordingly.

Senator ROBERTS: But you haven’t done any studies on the retention specifically of the spike proteins? The COVID injections dramatically increased the spike protein. You haven’t done any studies of that?

Prof. Lawler: I’m happy to have any additional response, but what I would highlight is that our role as a regulator is to assess evidence that is brought to us, and we undertake that assessment in the evaluation.

Senator ROBERTS: So you don’t go looking for it?

Prof. Lawler: We utilise that evidence in the assessment and evaluation of products, and we utilise the pharmacovigilance and post-market surveillance exercises that I’ve highlighted.

I asked Minister Gallagher how many vaccines are provided with an indemnity protection clause by the Australian government whereby those harmed cannot sue the company because the government has taken on the responsibility for harm done. Her answer was that indemnity was put in place due to the emergency nature of COVID response in the early stages. However 14 different COVID products have received indemnity protection from the Australian government, and one of them as recently as the 10th of October 2023.

In response, the minister fell back on confidentiality of agreements between the government and vaccine providers. This is the public’s money – the government is there to serve the people of Australia, not keep secrets from them and coerce them into risky products with mandates that even the Health Secretary, Prof Murphy, has said this year were not justifiable. The risk, from COVID, never justified the risk from the trial injections. After all that has been exposed globally, that the government is still promoting these products is shocking.

In saying that all necessary approvals to ensure its safety were followed through the TGA, Minister Gallagher is not being straight with us. The TGA did not test the Pfizer, AstraZeneca and Moderna COVID shots. It relied on the regulators overseas where these products were made. In the case of Pfizer, these were incomplete and aborted trials. The true magnitude of the harm is being released in the Pfizer papers ordered to be released by a judge in the USA.

Why is the government hiding behind confidentiality and exposing taxpayers to the risk of paying for costly damages for injection injuries as well as paying for products that are turning out to be unsafe and ineffective. Products that the public is no longer taking up and which the Minister appears to be pushing like a pharmaceutical sales rep on commission.

Big Pharma’s Stranglehold on Government Revealed

Senator Katy Gallagher claimed that the COVID product indemnity was put in place to secure product supply in a competitive market during the emergency of the COVID outbreak.

Senator Gallagher is the Minister for Finance overseeing contingent liabilities in the budget. With 14 more indemnities for COVID products and the most recent one last month, I think it’s pretty clear that this has nothing to do with a health emergency. It has everything to do with Labor’s deals with Moderna to get its production plants into Australia and pave the way for the World Health Organisation’s plans for 400 new mRNA vaccines for human and animal use. These are being designed to replace 400 regular vaccines with expiring patents.

Why is the government normalising indemnities? The process removes the incentive on the manufacturer to produce a safe, high quality product since any harm is paid for by the taxpayers. Follow the money and it leads to a patent cliff, not better health. It also explains the ongoing and seemingly frantic messaging of ‘safe and effective’ with every mention of these injections in government. It’s a shame the disinformation legislation does not cover messaging by the Government, so much misinformation originates there.

Transcript | Exactly Who is Calling the Shots in Australia?

Senator ROBERTS: My question is to the Minister representing the Minister for Health and Aged Care, Senator Gallagher. How many vaccines are subject to an indemnity from the Australian government?

Senator Gallagher: Thank you, Senator Roberts. I’ll just see if I can provide you with an accurate answer. I do know that there were indemnity arrangements put in place under the former government for the vaccines that were approved then, in the early stages of the pandemic, and those indemnity arrangements continue. I think we have traversed this a bit at estimates. I’m not sure if there is anything else I can provide. Indemnity arrangements were put in place for the vaccines that the government procured to enable the national vaccine rollout program to be undertaken during the pandemic emergency. That was an important part of ensuring that we could procure the vaccine in the amount that we needed and provide it to the Australian people. I would also say that, whilst the indemnity arrangements were in place, all of the required approvals to ensure the safety of the vaccines—prior to the vaccines being rolled out—were followed, through the TGA processes, which we have also traversed at length in estimates. We also have the COVID-19 Vaccine Claims Scheme, which was established to run alongside the national rollout of the vaccine program. And I would say that it was an important response to the pandemic to ensure that we could get as many people vaccinated as possible in a safe way to ensure that we minimised the impact of significant disease and also, at the very serious end, the deaths that occurred from contracting COVID-19.

Senator ROBERTS: Indemnities have been issued for 14 different COVID products. Each new COVID vaccine or shot has been given an indemnity, the most recent on 10 October 2023. With demand for the booster down to 5½ per cent for those under 65, and with multiple vendors, the argument that indemnities are needed to get stock is a patent nonsense. What is the real reason for these new indemnities, issued only six weeks ago?

Senator Gallagher: I can’t go into the confidential agreements that have been reached in procuring vaccines. These are agreements that are reached between the government and the vaccine provider, and we do so in a way that allows for the rollout of continued vaccination and booster shots to protect people from COVID-19. These are the arrangements that were entered into during the pandemic. Those arrangements are continuing. We think there’s a very important public health reason to ensure that we are procuring vaccines and making them available so people can take their booster. I would say that booster levels remain low—and we do want to see those increase—and that people should go and get their booster if they’re ready for one or if they’re six months past the last COVID-19 bout.

Senator ROBERTS: Minister, you won’t explain to the taxpayers why you’re using their money and putting it at risk, so I’ll ask a second supplementary. This government has offered Moderna an indemnity for every vaccine or shot manufactured in its new Australian factory, currently under construction, including regular non-pandemic vaccines. Why has your government not been honest in telling taxpayers they are paying for new vaccine harm during the COVID period and for all time?

Senator Gallagher: I’m not sure what Senator Roberts is referring to, and I reject the claim that we are somehow using taxpayers’ money and causing vaccine harm. That is not appropriate, and I absolutely categorically reject that. If there is anything further I can provide Senator Roberts around the arrangements with Moderna in particular, I am happy to arrange that. I don’t have that information before me, but I do accept that governments do negotiate agreements with companies around the supply and availability of medicines—and vaccines, in this instance—to ensure that we are able to provide the medicines Australia needs and also ensure that we have enough of the vaccines to provide the appropriate coverage, particularly for COVID-19 protection.

Transcript | Big Pharma’s Stranglehold on Government Revealed

I move: 

That the Senate take note of the answers given by the Minister for Finance (Senator Gallagher) to questions without notice I asked today relating to vaccine indemnities. 

Senator Gallagher is the Minister for Finance and is overseeing contingent liabilities in the budget. Although I prefer the words ‘fake-cine’ or ‘injectable’, what these products are not are vaccines. A vaccine prevents a person getting and transmitting an illness; these COVID ‘fake-cines’ do neither. Australia first provided indemnities in 2015 under the previous Liberal government for mpox and flu vaccines. Those indemnities are still in place. 

Now we have 14 more indemnities for COVID products, and they’ll be permanent. Labor’s deal to get Moderna’s production plant into Australia was revealed last week. Any vaccine manufactured in Moderna’s Australian factory, which is now under construction, will receive an indemnity. The agreement sets out that these vaccines will be indemnified as part of a pandemic vaccine advance-purchase agreement and additionally as part of a routine, non-pandemic vaccine supply agreement. In other words, every vaccine made will be indemnified with no word about testing. The new Moderna indemnity extends to routine vaccine supply, and the minister is not able to claim securing supply in a crisis. 

The World Health Organization has mentioned that there are 400 mRNA vaccines and products under development to replace conventional vaccines with expired patents. The attraction of mRNA is protecting profit from the patent cliff—not protecting better health. Those products will be for humans, livestock and pets. Our health authorities and politicians are promoting experimental mRNA products and, in so doing, risking everyday Australians’ health. I was hoping to hear why in the minister’s answer. Why is the government normalising indemnities, giving foreign multinational pharmaceutical companies blanket indemnities so they can avoid being accountable and encouraging companies to lie in their clinical trials, fudge efficacy data and cover up enduring death, as Pfizer was proven to have done in their COVID ‘fake-cine’ development? This question is not going away. We will relentlessly hound you down. 

The Labor government has done everything it can to avoid the scrutiny of a Royal Commission into COVID despite promising a Royal Commission on several occasions. Instead, PM Albanese has announced an inquiry that is guaranteed to be a whitewash to try an appease the Australian public who have been waiting for the Royal Commission.

I asked the minister why the government is afraid of a Royal Commission. Her answer was instead directed at the inhouse inquiry which is essentially three insiders investigating their mates. This is a travesty after the suffering, disruption and death that the COVID years brought to Australia.

This inquiry is a cover-up. Australians deserve a Royal Commission to bring the truth to light and prevent the same mistakes from happening again.

Transcript

Senator ROBERTS: Thank you. Minister, why do you fear a COVID royal commission, and is your support for the Chief Medical Officer and the TGA unequivocal?

Senator Gallagher: In relation to the second part, yes, absolutely. In relation to the first part, there is nothing to fear about the COVID inquiry.

Senator ROBERTS: There certainly isn’t.

Senator Gallagher: Hopefully genuine learnings will come out of it and we’ll all be better prepared for the next time we have a pandemic like that.

Senator ROBERTS: Thank you, Minister.

Australia’s premier vaccine sales advocate, the National Centre for Immunisation Research and Surveillance (NCIRS) is in charge of recommending if the federal government should add more vaccines to the schedule. Yet it’s the same organisation monitoring for adverse events from the vaccines it promotes. I asked the Minister if that sounds like a suitable arrangement to her. I also asked why the Chair of NCIRS is also the chair of the government’s advisory committee on vaccines. Should the person who promotes new vaccines be a different person to the one looking for harms caused by the vaccine?

I understand that grant funding received by the Chair of the NCIRS is substantial and raises conflict of interest issues.

There is an obvious reluctance to confront the possibility of conflicts of interest by the government and its drug regulatory authority. We only need to look at the situation with Dr Fauci, with his vast research grants and his position as both the advisor, the safety officer and the marketeer of the products to understand the potential for conflicts of interest leading to harm.

Transcript

CHAIR: Senator Roberts, we are coming towards the end of your block.

Senator ROBERTS: This is a scoping question to find out why the federal government funded National Centre for Immunisation Research and Surveillance is not present at estimates. They bill themselves as Australia’s leading immunisation organisation that provides expert evidence on vaccine preventable diseases and all aspects of immunisation to inform policy and planning in Australia and our region. Why aren’t they here at estimates?

Prof. Kelly: Senator, they are not an agency of the Commonwealth. They are a research institute, in fact. They do some work for us in relation to surveillance and research into immunisation, as their name suggests. We do have the chair of ATAGI online. He does not work at NCIRS. NCIRS is a very strong supporter of the ATAGI work. If there is a question specifically in relation to that—

Senator ROBERTS: Well, I understand the chair of NCIRS is also the chair of your advisory committee on vaccines, which recommends vaccines to the government. Is that correct?

Prof. Kelly: That’s a matter for the TGA. She is on that committee.

Prof. Lawler: I understand that’s correct.

Senator ROBERTS: Thank you. A program within the NCIRS is AusVaxSafety, which monitors safety signals, meaning adverse events from vaccinations through the body. There is the Adverse Events Following
Immunisation Clinical Assessment Network, or AEFI-CAN. How do you come up with all these acronyms? Here we have an organisation which, according to their About Us website page, is Australia’s premier vaccine sales advocate. The NCIRS is in charge of recommending if the federal government should add more vaccines to the schedule. That same organisation also monitors for adverse events from the vaccines it promotes. Minister, does that sound like a suitable arrangement to you?

Senator Gallagher: Sorry, Senator Roberts, you will have to repeat that.

Senator ROBERTS: We have an organisation—

Senator Gallagher: Is this ATAGI?

Senator ROBERTS: No, NCIRS. It is in charge of recommending if the federal government should add more vaccines to the schedule. That same organisation also monitors for adverse events from the vaccines it promotes. So it advocates for vaccines and it supposedly monitors for the events.

Senator Gallagher: That is not part of the regulatory framework of government.

Prof. Kelly: The TGA is the main provider of information about adverse events from vaccination. The NCIRS does run something. It’s actually on behalf of NSW Health, as I understand it, but we can place that on notice.

Senator Gallagher: The TGA provides reports regularly online.

Prof. Lawler: So in addition to what both the minister and Professor Kelly have said, the TGA undertakes both approval and post-approval monitoring of adverse events associated with approved goods. We do produce
and publish the database of adverse event notifications. I don’t know whether Elspeth Kay, our assistant secretary from the pharmacovigilance branch, would have anything to add.

Senator ROBERTS: Let’s move on. My interest here is possible conflicts of interest. Minister, you had the same person, Professor McCartney, as chair of all these bodies—the ones I went through before that question.
Should the person who promotes new vaccines be a different person to the one looking for harms caused by the vaccine? You seem to set up Professor McCartney as some sort of vaccine queen. Is it correct that Professor McCartney has received $65 million in research grants over the last five or so years? If so, what were those research grants for? What body of work did those grants produce, if anything? Could I have that on notice?

Senator Gallagher: I think Professor Kelly might be able to answer some of that.

Prof. Kelly: I can answer that.

Senator Gallagher: Can I just say as a general rule that I do think it’s unfortunate that individuals are named in this way with no right of reply in the context that you are raising this. I will put that on the record.

Prof. Kelly: Professor McCartney is the head of the NCIRS. She is a world-recognised expert in immunology and infectious diseases. She is a paediatrician who works at Westmead Hospital. She has multiple hats. She is part of an advisory group for the minister.

Senator ROBERTS: Excuse me, Professor Kelly. I’m not interested in her qualifications. I want to know her research grants.

Senator Gallagher: I think it’s deeply relevant to the aspersions that you seem to having about her.

Senator ROBERTS: I want to know her research grants—

Senator Gallagher: And her role.

Senator ROBERTS: I want to know her research grants and how much money she has received.

Prof. Kelly: I will finish, Senator. She is, as you’ve said, the chair of an advisory committee to the TGA. It does not make decisions. She is a member of ATAGI, which is an advisory group for the minister and does not
make decisions. In terms of research grants, we have the NHMRC, but they might need to take that on notice. She probably has other sources of funds. I can’t talk to the $65 million.

Senator ROBERTS: Can I get the answers on notice, please?

Prof. Kelly: We can take that on notice, yes.

Senator ROBERTS: I want a list of the $65 million in research grants over the last five years.

Senator Gallagher: I think that information would be publicly available. You seem to be able to do a fair bit of research on her. I’m sure you can do the same. If there are NHMRC grants, they will all be available publicly.

Prof. Lawler: I will add to Professor Kelly’s comments. I’m taking the imputation that the funding somehow does lead to a conflict. The two elements that you wrote—

Senator ROBERTS: No. It’s not only the funding.

CHAIR: Senator Roberts, you do need to let the witnesses finish their sentences.

Prof. Lawler: You raise two elements. One is that Professor McCartney decides which vaccines are added. As Professor Kelly has indicated, her role is as the chair of an advisory committee with the NHMRC that advises the delegate to make those determinations. Her role is to identify the harms that derive from these vaccines. That is the role of the pharmacovigilance function within the TGA.